J. Gautier

发表

Reasons for acceptance and refusal of early palliative care in patients included in early-phase clinical trials in a regional comprehensive cancer centre in France: protocol for a qualitative study

H. Vanacker, V. Christophe, F. Ducimetière, 2022, BMJ Open.

Toward Improved Diagnosis Accuracy and Treatment of Children, Adolescents, and Young Adults With Ependymoma: The International SIOP Ependymoma II Protocol

D. Frappaz, M. Massimino, R. Grundy, 2022, Frontiers in Neurology.

Intubation decision criteria in adult epiglottitis.

S. Boucher, L. Laccourreye, J. Gautier, 2020, European annals of otorhinolaryngology, head and neck diseases.

Designing exploratory partnerships in Southeast Asia: The challenge of building a sustainable ecosystem to address chronic malnutrition

K. Levillain, S. Hooge, J. Gautier, 2016 .

High mortality rate in cancer patients with symptoms of COVID-19 with or without detectable SARS-COV-2 on RT-PCR

J. Blay, I. Ray-Coquard, P. Saintigny, 2020, European Journal of Cancer.

Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.

J. Blay, F. Bertucci, A. Cesne, 2016, The Lancet. Oncology.

Final results of the multicenter randomized phase II PAZOGIST trial evaluating the efficacy of pazopanib (P) plus best supportive care (BSC) vs BSC alone in resistant unresectable metastatic and/or locally advanced gastrointestinal stromal tumors (GIST).

J. Blay, F. Bertucci, A. Cesne, 2015 .

Transluminal recanalization of occluded iliac arteries: a surgical experience.

V. Vidal, A. Cardon, J. Cardon, 1995, Annals of vascular surgery.

Survival After End-Stage Renal Failure: Preventing Cardiac Death in End-Stage Renal Disease Patients

E. Weinhandl, Kristine M. Kubisiak, J. Gautier, 2019, EMJ Nephrology.

Development of Randomized Trials in Adults with Medulloblastoma—The Example of EORTC 1634-BTG/NOA-23

M. Weller, T. Gorlia, S. Pfister, 2021, Cancers.

Sequential sorafenib and sunitinib for renal cell carcinoma.

A. Ravaud, C. Balleyguier, B. Escudier, 2009, The Journal of urology.

Intermittent versus continuous administration of pazopanib in progressive radioiodine refractory thyroid carcinoma: Final results of the randomised, multicenter, open-label phase II trial PAZOTHYR.

P. Niccoli, C. Chougnet, S. Bardet, 2021, European journal of cancer.

The European Society of Paediatric Oncology Ependymoma-II program Core-Plus model: Development and initial implementation of a cognitive test protocol for an international brain tumour trial.

D. Frappaz, M. Massimino, R. Grundy, 2019, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

Sequential use of sorafenib and sunitinib in renal cancer: Retrospective analysis in 90 patients

A. Ravaud, C. Balleyguier, S. Oudard, 2007 .

Bladder Sequential Sorafenib and Sunitinib for Renal Cell Carcinoma

A. Ravaud, C. Balleyguier, B. Escudier, 2022 .

LBA45A RANDOMIZED MULTICENTRE PHASE II STUDY OF PAZOPANIB PLUS BEST SUPPORTIVE CARE (BSC) VS BSC ALONE IN METASTATIC GASTROINTESTINAL STROMAL TUMORS (GIST) RESISTANT TO IMATINIB AND SUNITINIB

J. Blay, F. Bertucci, B. Bui, 2014 .